KRAS and non-small cell lung carcinoma: In contrast, other genes such as TP53 and KRAS, the mutations of which are among the most prevalent alterations in NSCLC (detected in 40–50% and 25–35% of patients, respectively), currently remain orphans of approved targeted therapies [5].